Abstract submission extended until 30th November 2018
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today, we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a wide range of therapies, and a continued determination to provide real solutions-from medicines to support programs and more-we strive to make life better for all those affected by diabetes around the world. For more information, visit www.lillydiabetes.com.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 119,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit http://www.novartis.com.
MSD also known as Merck Sharp & Dohme Corp., (a subsidiary of Merck & Co., Inc.,Whitehouse Station, NJ, USA) is a global research-driven pharmaceutical companydedicated to putting patients first. Established in 1891, MSD discovers, develops,manufactures and markets vaccines and medicines to address unmet medical needs.MSD has been present for over than 30 years in the GULF region. MSD GULF operatesthroughout offices based in the UAE, Kuwait, Bahrain, Qatar & Oman and ranksamongst the leading pharmaceutical companies throughout the GULF region. Throughits local distributors, MSD GULF provides innovative medications in several diseaseentities. These include products for Anti- Infectives, Cardiovascular, Asthma & Allergy,Diabetes, HCV, HIV, Pain & Inflammation, Osteoporosis, Oncology, Fertility,Ophthalmic, and Anesthesia in addition to several specialized Vaccines.
About Boehringer Ingelheim
Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the industry's top 20 pharmaceutical companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.
Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects, such as the "Making More Health" initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees' different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.
At Sanofi Diabetes, our priorities are focused on the needs of people with diabetes around the world. With a century of experience in this area, we strive to help people manage the complex challenge of diabetes by delivering a range of innovative, personalized solutions integrated across diagnostics, therapies, devices and services. Because we understand the daily impact of diabetes and our patients' aspirations, we know how to improve their quality of life. We want people to live 'beyond' diabetes, to achieve aspirations and to make the most of everyday!
Servier is an international pharmaceutical company governed by a foundation and headquartered in Suresnes (France). With a strong international presence in 148 countries and a turnover of 4 billion euros in 2016, Servier employs 21 000 people worldwide. Corporate growth is driven by Servier's constant search for innovation in five areas of excellence: cardiovascular diseases, diabetes, cancers, immune-inflammatory diseases, and neurodegenerative diseases, as well as by its activities in high-quality generic drugs. Being completely independent, the Group reinvests 25% of turnover (excluding generics) in research and development and uses all its profits for growth.
More information: www.servier.com
Headquartered in Denmark, Novo Nordisk was established in 1923 and currently employs around 42,600 people in 75 countries and markets its products in more than 180 countries.
Novo Nordisk is a global healthcare leader in diabetes care, offering one of the broadest portfolios of diabetes products in the industry and is a supplier of more than half of the world's insulin with 26.8 million people using its products. Novo Nordisk also helps people defeat other serious chronic conditions as haemophilia, growth disorders and obesity.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Founded in Darmstadt, Germany, in 1668 by Friedrich Jacob Merck, we are the world's oldest pharmaceutical and chemical company. Today, the Merck family remains the majority owner of the company. Over the course of 350 years, we have become a truly global company.
Our approximately 50,000 people work in 66 countries and are united by their passion for new ideas, the possibilities of technology, and the potential to make a difference in the world. In healthcare we help to create, improve and prolong life - continuously working to make a lasting difference to patients' lives. Our portfolio includes medicines to treat cancer, multiple sclerosis, infertility, growth disorders, cardiovascular diseases, diabetes and thyroid disorders. We develop high-quality products that protect every member of your family so that they can enjoy healthier, happier lives every day
We are known as Merck internationally. In the United States and Canada, we operate as EMD Serono in the Biopharma business, as MilliporeSigma in the Life Science business, and as EMD Performance Materials in the materials business.
Hikma develop, manufacture and market a broad range of branded and non-branded generic pharmaceutical products across the US, the MENA region and Europe. Hikma is also a leading licensing partner in the MENA region. Their operations span more than 50 countries and are conducted through three business segments (Brabded, Injectables, and Generics).
Pic Solution is a leading Italian healthcare brand.
Its diabetes portfolio features the Insupen 33Gx4mm pen needle, representing the peak of a range which includes also a complete span of sizes (from 32G to 29G). Thanks to the Extr3me sharpening technology, all Insupen pen needles provide a comfortable injection, while the High Flow Thin Wall cannula enhances the insulin flow. BGMs, syringes, lancets and footcare products complete the assortment.
As a global leader in diabetes care, Abbott is constantly working to deliver the highest quality products and unwavering support to our customers. Consistent and accurate glucose monitoring is the foundation of any diabetes management plan so we're committed to continuous improvement in the way patients and professionals measure, track and analyze glucose levels. PEOPLE ACROSS THE WORLD COUNT on the FreeStyle family of glucose monitoring systems to help them manage their diabetes. HEALTHCARE PROFESSIONALS depend on Abbott to provide them with state of the art tools to help them care for their patients with diabetes. WE'RE INNOVATING TODAY FOR A HEALTHIER TOMORROW through a steadfast commitment to research, technology and state-of-the-art manufacturing, Abbott has developed a diverse portfolio of breakthrough diabetes products designed to meet the needs of each unique patient. Our innovative product development program is responsible for several groundbreaking technologies. Keep looking to our dedicated teams for the next generation of highly innovative and effective glucose monitoring products. We aim to set the standard for helping patients and healthcare providers to potentially achieve the best health outcomes.
BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and healthcare worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures and support the management of diabetes.
Since 1924, when BD manufactured the world's first specialized insulin syringe, BD has been on the forefront of innovation in insulin delivery. BD's culture of innovation and continuous improvement has enhanced the patient experience to enable better diabetes therapy and outcomes. BD pen needles and insulin syringes are designed with leading technology to support earlier initiation and better adherence to injectable therapies, helping diabetes patients live healthier lives.
About SBI Neopharma
SBI Neopharma is a joint venture between SBI Pharmaceuticals Co. Ltd. and Neopharma LLC for the research, production and global sales for medicines, medical devices, cosmetics and health foods utilizing 5-ALA (5-aminolevulinic acid). SBI Pharmaceuticals is part of the SBI group, a Tokyo based financial services organization with varied business interests. Neopharma is a UAE based global pharmaceutical company founded by Dr. B.R. Shetty.
NatuALA (5 Amino Levulinic Acid Phosphate and Sodium Ferrous Citrate)
The product is a fixed dose combination of 5 amino levulinic acid phosphate (5ALA) and sodium ferrous citrate (SFC). 5 ALA is an endogenous non peptide amino acid and is the first precursor of heme biosynthesis. Reduction of cytochrome activity and mitochondrial dysfunction has been corelated with lower levels of 5ALA in body which in turn results in lower basal metabolic rate. Mitochondrial dysfunction has been associated with insulin resistance, type 2 diabetes mellitus and accumulation of cholesterol in body and weight gain. Excess heme in human body results in activation of heme oxygenase I (HO-1) enzyme which results in production of potent antioxidants like bilirubin and biliverdin emphasizing role of 5 ALA as antioxidant. 5 ALA and SFC in combination is a very good dietary supplement that basically leads to mitochondrial activation leading to reduction in glucose levels of prediabetic and diabetic patients and prevention of fat accumulation.
LifeScan Inc. is a Johnson & Johnson company; For over thirty years, LifeScan Inc., the maker of OneTouch® products, has had an unwavering commitment to improving the quality of life for people living with diabetes.
In 1987, LifeScan Inc. introduced the first OneTouch® meter that had the simplicity and accuracy to redefine self-monitoring of blood glucose. And we're proud that, today, OneTouch® meters and test strips are used across the globe by more than 19 million people.
In 2014 LifeScan, Johnson & Johnson Diabetes care companies was the first to offer patients self-monitoring blood glucose meters with the new technology of ColourSureTM Technology which help patients to better understand & interpret their blood glucose readings
For Sponsorship and Exhibition inquiries, please contact firstname.lastname@example.org
Emirates Diabetes & Endocrine Congress (EDEC) is organized by Emirates Diabetes Society. EDEC is the region's premier platform to update attendees on the recent advances in the ever-changing field of diabetes and endocrine diseases.